Does the media prefer KYMR or NUVB?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Kymera Therapeutics and 5 mentions for Nuvation Bio. Kymera Therapeutics' average media sentiment score of 0.48 beat Nuvation Bio's score of -0.32 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SYRE or NUVB?

In the previous week, Nuvation Bio had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.27 beat Nuvation Bio's score of -0.32 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NUVB or PTGX?

In the previous week, Protagonist Therapeutics had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 5 mentions for Nuvation Bio. Protagonist Therapeutics' average media sentiment score of 0.73 beat Nuvation Bio's score of -0.32 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or RYTM?

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 5 mentions for Nuvation Bio. Rhythm Pharmaceuticals' average media sentiment score of 0.61 beat Nuvation Bio's score of -0.32 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or NUVB?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 5 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 1.41 beat Nuvation Bio's score of -0.32 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nuvation Bio (NUVB) Competitors

$4.62 -0.28 (-5.71%)

As of 12:27 PM Eastern

Compare

NUVB vs. KYMR, SYRE, PTGX, RYTM, and MIRM

Should you buy Nuvation Bio stock or one of its competitors? MarketBeat compares Nuvation Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvation Bio include Kymera Therapeutics (KYMR), Spyre Therapeutics (SYRE), Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Nuvation Bio compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Nuvation Bio has a net margin of -102.06% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Nuvation Bio	-102.06%	-44.10%	-23.80%

61.7% of Nuvation Bio shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nuvation Bio has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	153.51	-$311.35M	-$3.57	N/A
Nuvation Bio	$62.90M	25.63	-$204.63M	-$0.43	N/A

Kymera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Kymera Therapeutics had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Kymera Therapeutics and 5 mentions for Nuvation Bio. Kymera Therapeutics' average media sentiment score of 0.48 beat Nuvation Bio's score of -0.32 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics presently has a consensus price target of $118.10, indicating a potential upside of 61.40%. Nuvation Bio has a consensus price target of $12.50, indicating a potential upside of 169.98%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Kymera Therapeutics beats Nuvation Bio on 9 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Spyre Therapeutics has higher earnings, but lower revenue than Nuvation Bio. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,192.11	-$155.20M	-$2.08	N/A
Nuvation Bio	$62.90M	25.63	-$204.63M	-$0.43	N/A

Spyre Therapeutics presently has a consensus price target of $90.25, suggesting a potential upside of 22.44%. Nuvation Bio has a consensus price target of $12.50, suggesting a potential upside of 169.98%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Nuvation Bio had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.27 beat Nuvation Bio's score of -0.32 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Spyre Therapeutics' return on equity of -42.88% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Nuvation Bio	-102.06%	-44.10%	-23.80%

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Spyre Therapeutics beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Protagonist Therapeutics?

Nuvation Bio (NYSE:NUVB) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Nuvation Bio has a net margin of -102.06% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Protagonist Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	25.63	-$204.63M	-$0.43	N/A
Protagonist Therapeutics	$46.02M	132.20	-$130.15M	-$1.81	N/A

Nuvation Bio presently has a consensus target price of $12.50, indicating a potential upside of 169.98%. Protagonist Therapeutics has a consensus target price of $115.21, indicating a potential upside of 21.79%. Given Nuvation Bio's higher probable upside, research analysts plainly believe Nuvation Bio is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Protagonist Therapeutics had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 5 mentions for Nuvation Bio. Protagonist Therapeutics' average media sentiment score of 0.73 beat Nuvation Bio's score of -0.32 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Nuvation Bio on 11 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Rhythm Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 5 mentions for Nuvation Bio. Rhythm Pharmaceuticals' average media sentiment score of 0.61 beat Nuvation Bio's score of -0.32 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio currently has a consensus price target of $12.50, indicating a potential upside of 169.98%. Rhythm Pharmaceuticals has a consensus price target of $131.81, indicating a potential upside of 55.13%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	25.63	-$204.63M	-$0.43	N/A
Rhythm Pharmaceuticals	$189.76M	30.69	-$196.54M	-$3.13	N/A

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

61.7% of Nuvation Bio shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Rhythm Pharmaceuticals beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Nuvation Bio has a net margin of -102.06% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Mirum Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.76	-$23.36M	-$13.61	N/A
Nuvation Bio	$62.90M	25.63	-$204.63M	-$0.43	N/A

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 5 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 1.41 beat Nuvation Bio's score of -0.32 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus price target of $137.64, suggesting a potential upside of 49.64%. Nuvation Bio has a consensus price target of $12.50, suggesting a potential upside of 169.98%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

61.7% of Nuvation Bio shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Mirum Pharmaceuticals beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.61B	$3.26B	$6.26B	$23.13B
Dividend Yield	N/A	2.33%	2.69%	4.09%
P/E Ratio	-10.77	17.75	22.35	31.16
Price / Sales	25.63	323.71	555.60	14.72
Price / Cash	N/A	116.27	42.31	24.78
Price / Book	5.26	6.55	9.82	4.68
Net Income	-$204.63M	$24.20M	$3.56B	$1.07B
7 Day Performance	-2.01%	-3.25%	-1.16%	-0.38%
1 Month Performance	3.46%	0.48%	3.85%	0.52%
1 Year Performance	88.59%	47.06%	27.33%	25.86%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	3.0311 of 5 stars	$4.62 -5.7%	$12.50 +170.6%	+110.5%	$1.61B	$62.90M	N/A	60
KYMR Kymera Therapeutics	2.2817 of 5 stars	$78.89 flat	$118.10 +49.7%	+65.3%	$6.49B	$39.21M	N/A	170
SYRE Spyre Therapeutics	2.8177 of 5 stars	$74.05 flat	$90.25 +21.9%	+349.1%	$6.43B	$890K	N/A	73	Positive News
PTGX Protagonist Therapeutics	2.6064 of 5 stars	$99.19 flat	$115.21 +16.2%	+85.8%	$6.38B	$46.02M	N/A	120	Insider Trade
RYTM Rhythm Pharmaceuticals	2.7841 of 5 stars	$87.84 flat	$131.81 +50.1%	+32.5%	$6.02B	$189.76M	N/A	140	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. KYMR, SYRE, PTGX, RYTM, and MIRM

How does Nuvation Bio compare to Kymera Therapeutics?

Summary

How does Nuvation Bio compare to Spyre Therapeutics?

Summary

How does Nuvation Bio compare to Protagonist Therapeutics?

Summary

How does Nuvation Bio compare to Rhythm Pharmaceuticals?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. KYMR, SYRE, PTGX, RYTM, and MIRM

How does Nuvation Bio compare to Kymera Therapeutics?

Is KYMR or NUVB more profitable?

Do institutionals and insiders believe in KYMR or NUVB?

Which has better valuation and earnings, KYMR or NUVB?

Which has more risk & volatility, KYMR or NUVB?

Does the media prefer KYMR or NUVB?

Do analysts rate KYMR or NUVB?

Summary

How does Nuvation Bio compare to Spyre Therapeutics?

Which has better earnings and valuation, SYRE or NUVB?

Do analysts prefer SYRE or NUVB?

Does the media refer more to SYRE or NUVB?

Which has more risk & volatility, SYRE or NUVB?

Is SYRE or NUVB more profitable?

Do insiders and institutionals hold more shares of SYRE or NUVB?

Summary

How does Nuvation Bio compare to Protagonist Therapeutics?

Do institutionals and insiders believe in NUVB or PTGX?

Which has more risk and volatility, NUVB or PTGX?

Is NUVB or PTGX more profitable?

Which has better valuation & earnings, NUVB or PTGX?

Do analysts prefer NUVB or PTGX?

Does the media favor NUVB or PTGX?

Summary

How does Nuvation Bio compare to Rhythm Pharmaceuticals?

Which has more risk & volatility, NUVB or RYTM?

Does the media refer more to NUVB or RYTM?

Do analysts prefer NUVB or RYTM?

Which has higher earnings and valuation, NUVB or RYTM?

Is NUVB or RYTM more profitable?

Do institutionals & insiders believe in NUVB or RYTM?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Is MIRM or NUVB more profitable?

Which has higher earnings and valuation, MIRM or NUVB?

Does the media prefer MIRM or NUVB?

Which has more volatility & risk, MIRM or NUVB?

Do analysts prefer MIRM or NUVB?

Do institutionals and insiders believe in MIRM or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools